BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 17625792)

  • 21. The potential role of APOBEC3G in limiting replication of hepatitis B virus.
    Mohamadkhani A; Pourdadash A; Tayebi S; Estakhri A; Nazem H; Sotoudeh M; Poustchi H
    Arab J Gastroenterol; 2012 Dec; 13(4):170-3. PubMed ID: 23432984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. APOBEC3G directly binds Hepatitis B virus core protein in cell and cell free systems.
    Zhao D; Wang X; Lou G; Peng G; Li J; Zhu H; Chen F; Li S; Liu D; Chen Z; Yang Z
    Virus Res; 2010 Aug; 151(2):213-9. PubMed ID: 20510315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Target cell APOBEC3C can induce limited G-to-A mutation in HIV-1.
    Bourara K; Liegler TJ; Grant RM
    PLoS Pathog; 2007 Oct; 3(10):1477-85. PubMed ID: 17967058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comment on "Inhibition of hepatitis B virus replication by APOBEC3G".
    Rösler C; Köck J; Malim MH; Blum HE; von Weizsäcker F
    Science; 2004 Sep; 305(5689):1403; author reply 1403. PubMed ID: 15353783
    [No Abstract]   [Full Text] [Related]  

  • 25. Unedited inhibition of HBV replication by APOBEC3G.
    Seppen J
    J Hepatol; 2004 Dec; 41(6):1068-9. PubMed ID: 15582148
    [No Abstract]   [Full Text] [Related]  

  • 26. Dual effect of APOBEC3G on Hepatitis B virus.
    Noguchi C; Hiraga N; Mori N; Tsuge M; Imamura M; Takahashi S; Fujimoto Y; Ochi H; Abe H; Maekawa T; Yatsuji H; Shirakawa K; Takaori-Kondo A; Chayama K
    J Gen Virol; 2007 Feb; 88(Pt 2):432-440. PubMed ID: 17251560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G.
    Rose KM; Marin M; Kozak SL; Kabat D
    AIDS Res Hum Retroviruses; 2005 Jul; 21(7):611-9. PubMed ID: 16060832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of hepatitis B virus replication by APOBEC3G.
    Turelli P; Mangeat B; Jost S; Vianin S; Trono D
    Science; 2004 Mar; 303(5665):1829. PubMed ID: 15031497
    [No Abstract]   [Full Text] [Related]  

  • 29. Genetic editing of HBV DNA by monodomain human APOBEC3 cytidine deaminases and the recombinant nature of APOBEC3G.
    Henry M; Guétard D; Suspène R; Rusniok C; Wain-Hobson S; Vartanian JP
    PLoS One; 2009; 4(1):e4277. PubMed ID: 19169351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif.
    Pery E; Rajendran KS; Brazier AJ; Gabuzda D
    J Virol; 2009 Mar; 83(5):2374-81. PubMed ID: 19109396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A3G-induced mutations show a low prevalence and exhibit plus-strand regional distribution in hepatitis B virus DNA from patients with non-hepatocellular carcinoma (HCC) and HCC.
    Ren F; Li W; Zhao S; Wang L; Wang Q; Li M; Xiang A; Guo Y
    J Med Virol; 2021 Jun; 93(6):3672-3678. PubMed ID: 32779759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. G to A hypermutation of hepatitis B virus.
    Noguchi C; Ishino H; Tsuge M; Fujimoto Y; Imamura M; Takahashi S; Chayama K
    Hepatology; 2005 Mar; 41(3):626-33. PubMed ID: 15726649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA mutagenic activity and capacity for HIV-1 restriction of the cytidine deaminase APOBEC3G depend on whether DNA or RNA binds to tyrosine 315.
    Polevoda B; Joseph R; Friedman AE; Bennett RP; Greiner R; De Zoysa T; Stewart RA; Smith HC
    J Biol Chem; 2017 May; 292(21):8642-8656. PubMed ID: 28381554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RNA editing of hepatitis B virus transcripts by activation-induced cytidine deaminase.
    Liang G; Kitamura K; Wang Z; Liu G; Chowdhury S; Fu W; Koura M; Wakae K; Honjo T; Muramatsu M
    Proc Natl Acad Sci U S A; 2013 Feb; 110(6):2246-51. PubMed ID: 23341589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H.
    Soros VB; Yonemoto W; Greene WC
    PLoS Pathog; 2007 Feb; 3(2):e15. PubMed ID: 17291161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Associations between activation-induced cytidine deaminase/apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like cytidine deaminase expression, hepatitis B virus (HBV) replication and HBV-associated liver disease (Review).
    He X; Li J; Wu J; Zhang M; Gao P
    Mol Med Rep; 2015 Nov; 12(5):6405-14. PubMed ID: 26398702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
    Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
    J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The inhibition of hepatitis B virus by APOBEC cytidine deaminases.
    Janahi EM; McGarvey MJ
    J Viral Hepat; 2013 Dec; 20(12):821-8. PubMed ID: 24304451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different antiviral activities of natural APOBEC3C, APOBEC3G, and APOBEC3H variants against hepatitis B virus.
    Kanagaraj A; Sakamoto N; Que L; Li Y; Mohiuddin M; Koura M; Wakae K; Kurachi M; Muramatsu M; Kitamura K
    Biochem Biophys Res Commun; 2019 Oct; 518(1):26-31. PubMed ID: 31400856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection.
    Pion M; Granelli-Piperno A; Mangeat B; Stalder R; Correa R; Steinman RM; Piguet V
    J Exp Med; 2006 Dec; 203(13):2887-93. PubMed ID: 17145955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.